Format

Send to

Choose Destination
Br J Haematol. 2016 Sep;174(5):730-47. doi: 10.1111/bjh.14116. Epub 2016 May 23.

Efficacy and safety of darbepoetin alpha in patients with myelodysplastic syndromes: a systematic review and meta-analysis.

Author information

1
CHU de Grenoble, Clinique Universitaire d'Hématologie, Université Grenoble Alpes, Grenoble, France.
2
Hôpital St Louis/Université Paris 7, Paris, France.
3
Stanford University Medical Center, Stanford, CA, USA.
4
Amgen Inc., Thousand Oaks, CA, USA.
5
Amgen Inc., South San Francisco, CA, USA.

Abstract

We conducted a systematic review and meta-analysis to estimate the efficacy of darbepoetin alpha (DA) for treatment of myelodysplastic syndrome (MDS)-related anaemia. Eligible studies were prospective, interventional, and reported World Health Organization, French-American-British, or International Prognostic Scoring System (IPSS) criteria. Outcomes included erythroid response rate (primary); haemoglobin response; change in haemoglobin, transfusion status, and quality-of-life (QoL); and safety. Ten studies (N = 647) were analysed. Erythroid response rate range was 38-72%; median response duration range was 12-51+ months. Patients with erythropoietin (EPO) <100 iu/l had 35% [95% confidence interval (CI): 22-48%; P < 0·001) better response than patients with EPO >100 iu/l. Erythropoesis-stimulating agent (ESA)-naïve patients had 17% (95% CI: 3-32%; P = 0·022) greater response rate than those previously treated with ESA. Nonetheless, previously treated patients had response rates of 25-75%. Higher baseline haemoglobin levels, higher dose, transfusion-independence and low-risk IPSS status were reported by several studies to be associated with better response. QoL, transfusion rates and haemoglobin levels improved with treatment. Hypertension, thromboembolism and progression to acute myeloid leukaemia were reported in 2%, 1% and 1% of patients, respectively. This meta-analysis suggests that DA treatment can be useful for improving erythroid response in MDS patients with anaemia, even among patients previously treated with ESA.

KEYWORDS:

darbepoetin alpha; meta-analysis; myelodysplastic syndromes; systematic review

PMID:
27214305
PMCID:
PMC5089656
DOI:
10.1111/bjh.14116
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center